RxDoctor Payments DataLook up a doctor →

Carrie Evans, APRN

Family · Ardmore, OKNPI 1124795349

Payments from drug & device makers

$8,690in general payments, 2019–2025

Across 443 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • UCB, Inc.$803
  • Neurocrine Biosciences, Inc.$776
  • AbbVie$769
  • Teva Pharmaceuticals USA, Inc.$726
  • SK Life Science, Inc.$437
  • plus $3K from 41 others

What the payments were for

  • Consulting fees$1502%
  • Travel & lodging$1,08612%
  • Food & beverage$7,38785%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,690 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$100,310
Medicare patients
442
Services billed
4,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$94,011
UbrelvyUbrogepant34$46,128
Nurtec OdtRimegepant Sulfate25$36,908
Emgality PenGalcanezumab-Gnlm36$27,623
Aimovig AutoinjectorErenumab-Aooe37$26,985
Topiramate ErTopiramate12$14,077
Donepezil Hcl197$9,299
Lamotrigine115$7,988
Memantine Hcl107$5,440
Pregabalin54$4,283
Gabapentin159$4,033
Levetiracetam121$2,855
Topiramate78$2,390
Divalproex Sodium76$2,139
Primidone103$1,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$776$94,01111 claims
AbbVieUbrelvy$769$46,12834 claims
PfizerNurtec Odt$82$36,90825 claims
Upsher-smith Laboratories LLCTopiramate$60$2,39078 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$88$51213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.

Other family in Ardmore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →